The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.